AFT Pharmaceuticals Faces First Half Loss, Eyes Recovery

AFT Pharmaceuticals Ltd. (AU:AFP) has released an update.

AFT Pharmaceuticals anticipates announcing a $2 million operating loss for the first half of 2024 due to reduced international and Asian sales, influenced by factors like a South Korean doctors strike. Despite these setbacks, the company reports double-digit growth in Australia and New Zealand and remains optimistic about a sales recovery in the second half of the financial year. AFT remains well-capitalized and is exploring initiatives to improve its full-year forecast.

For further insights into AU:AFP stock, check out TipRanks’ Stock Analysis page.